Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1994 Jul;38(1):15–22. doi: 10.1111/j.1365-2125.1994.tb04316.x

The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes.

V Spaldin 1, S Madden 1, W F Pool 1, T F Woolf 1, B K Park 1
PMCID: PMC1364832  PMID: 7946932

Abstract

1. Tacrine (1,2,3,4-tetrahydro-9-aminoacridine-hydrochloride: THA) underwent metabolism in vitro by a panel (n = 12) of human liver microsomes genotyped for CYP2D6, in the presence of NADPH, to both protein-reactive and stable metabolites. 2. There was considerable variation in the extent of THA metabolism amongst human livers. Protein-reactive metabolite formation showed a 10-fold variation (0.6 +/- 0.1%-5.2 +/- 0.8% of incubated radioactivity mg-1 protein) whilst stable metabolites showed a 3-fold variation (24.3 +/- 1.7%-78.6 +/- 2.6% of incubated radioactivity). 3. Using cytochrome P450 isoform specific inhibitors CYP1A2 was identified as the major enzyme involved in all routes of THA metabolism. 4. There was a high correlation between aromatic and alicyclic hydroxylation (r = 0.92, P < 0.0001) consistent with these biotransformations being catalysed by the same enzymes. 5. Enoxacin (ENOX), cimetidine (CIM) and chloroquine (CQ) inhibited THA metabolism by a preferential decrease in the bioactivation to protein-reactive, and hence potentially toxic, species. The inhibitory potency of ENOX and CIM was increased significantly upon pre-incubation with microsomes and NADPH. 6. Covalent binding correlated with 7-OH-THA formation before (r = 0.792, P < 0.0001) and after (r = 0.73, P < 0.0001) inhibition by CIM, consistent with a two-step mechanism in the formation of protein-reactive metabolite(s) via a 7-OH intermediate. 7. The use of enzyme inhibitors may provide a useful tool for examining the relationship between the metabolism and toxicity of THA in vivo.

Full text

PDF
15

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Back D. J., Purba H. S., Staiger C., Orme M. L., Breckenridge A. M. Inhibition of drug metabolism by the antimalarial drugs chloroquine and primaquine in the rat. Biochem Pharmacol. 1983 Jan 15;32(2):257–263. doi: 10.1016/0006-2952(83)90553-1. [DOI] [PubMed] [Google Scholar]
  2. Back D. J., Tjia J., Mönig H., Ohnhaus E. E., Park B. K. Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. Eur J Clin Pharmacol. 1988;34(2):157–163. doi: 10.1007/BF00614553. [DOI] [PubMed] [Google Scholar]
  3. Bem J. L., Mann R. D. Danger of interaction between ciprofloxacin and theophylline. Br Med J (Clin Res Ed) 1988 Apr 16;296(6629):1131–1131. doi: 10.1136/bmj.296.6629.1131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bickett D. J., MacKenzie P. I., Veronese M. E., Miners J. O. In vitro approaches can predict human drug metabolism. Trends Pharmacol Sci. 1993 Aug;14(8):292–294. doi: 10.1016/0165-6147(93)90043-j. [DOI] [PubMed] [Google Scholar]
  5. Coleman M. D., Scott A. K., Breckenridge A. M., Park B. K. The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man. Br J Clin Pharmacol. 1990 Nov;30(5):761–767. doi: 10.1111/j.1365-2125.1990.tb03847.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Eagger S. A., Levy R., Sahakian B. J. Tacrine in Alzheimer's disease. Lancet. 1991 Apr 27;337(8748):989–992. doi: 10.1016/0140-6736(91)92656-m. [DOI] [PubMed] [Google Scholar]
  7. Farlow M., Gracon S. I., Hershey L. A., Lewis K. W., Sadowsky C. H., Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. JAMA. 1992 Nov 11;268(18):2523–2529. [PubMed] [Google Scholar]
  8. Faux S. P., Combes R. D. Interaction of cimetidine with cytochrome P450 and effect on mixed-function oxidase activities of liver microsomes. Hum Exp Toxicol. 1993 Mar;12(2):147–152. doi: 10.1177/096032719301200209. [DOI] [PubMed] [Google Scholar]
  9. First M. R., Schroeder T. J., Weiskittel P., Myre S. A., Alexander J. W., Pesce A. J. Concomitant administration of cyclosporin and ketoconazole in renal transplant recipients. Lancet. 1989 Nov 18;2(8673):1198–1201. doi: 10.1016/s0140-6736(89)91802-3. [DOI] [PubMed] [Google Scholar]
  10. Forsyth D. R., Surmon D. J., Morgan R. A., Wilcock G. K. Clinical experience with and side-effects of tacrine hydrochloride in Alzheimer's disease: a pilot study. Age Ageing. 1989 Jul;18(4):223–229. doi: 10.1093/ageing/18.4.223. [DOI] [PubMed] [Google Scholar]
  11. Fuhr U., Strobl G., Manaut F., Anders E. M., Sörgel F., Lopez-de-Brinas E., Chu D. T., Pernet A. G., Mahr G., Sanz F. Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. Mol Pharmacol. 1993 Feb;43(2):191–199. [PubMed] [Google Scholar]
  12. Fuhr U., Wolff T., Harder S., Schymanski P., Staib A. H. Quinolone inhibition of cytochrome P-450-dependent caffeine metabolism in human liver microsomes. Drug Metab Dispos. 1990 Nov-Dec;18(6):1005–1010. [PubMed] [Google Scholar]
  13. Galbraith R. A., Michnovicz J. J. The effects of cimetidine on the oxidative metabolism of estradiol. N Engl J Med. 1989 Aug 3;321(5):269–274. doi: 10.1056/NEJM198908033210501. [DOI] [PubMed] [Google Scholar]
  14. Hyland R., Gescher A., Thummel K., Schiller C., Jheeta P., Mynett K., Smith A. W., Mráz J. Metabolic oxidation and toxification of N-methylformamide catalyzed by the cytochrome P450 isoenzyme CYP2E1. Mol Pharmacol. 1992 Feb;41(2):259–266. [PubMed] [Google Scholar]
  15. Ioannoni B., Mason S. R., Reilly P. E., Winzor D. J. Evidence for induction of hepatic microsomal cytochrome P-450 by cimetidine: binding and kinetic studies. Arch Biochem Biophys. 1986 Jun;247(2):372–383. doi: 10.1016/0003-9861(86)90596-5. [DOI] [PubMed] [Google Scholar]
  16. Jensen J. C., Gugler R. Cimetidine interaction with liver microsomes in vitro and in vivo. Involvement of an activated complex with cytochrome P-450. Biochem Pharmacol. 1985 Jun 15;34(12):2141–2146. doi: 10.1016/0006-2952(85)90408-3. [DOI] [PubMed] [Google Scholar]
  17. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  18. Lancaster D. L., Adio R. A., Tai K. K., Simooya O. O., Broadhead G. D., Tucker G. T., Lennard M. S. Inhibition of metoprolol metabolism by chloroquine and other antimalarial drugs. J Pharm Pharmacol. 1990 Apr;42(4):267–271. doi: 10.1111/j.2042-7158.1990.tb05405.x. [DOI] [PubMed] [Google Scholar]
  19. Madden S., Back D. J., Orme M. L. Metabolism of the contraceptive steroid desogestrel by human liver in vitro. J Steroid Biochem. 1990 Feb;35(2):281–288. doi: 10.1016/0022-4731(90)90285-z. [DOI] [PubMed] [Google Scholar]
  20. Madden S., Woolf T. F., Pool W. F., Park B. K. An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes. Biochem Pharmacol. 1993 Jul 6;46(1):13–20. doi: 10.1016/0006-2952(93)90342-t. [DOI] [PubMed] [Google Scholar]
  21. Maesen F. P., Teengs J. P., Baur C., Davies B. I. Quinolones and raised plasma concentrations of theophylline. Lancet. 1984 Sep 1;2(8401):530–530. doi: 10.1016/s0140-6736(84)92617-5. [DOI] [PubMed] [Google Scholar]
  22. May D. G., Naukam R. J., Kambam J. R., Branch R. A. Cimetidine-carbaryl interaction in humans: evidence for an active metabolite of carbaryl. J Pharmacol Exp Ther. 1992 Sep;262(3):1057–1061. [PubMed] [Google Scholar]
  23. McGourty J. C., Silas J. H., Lennard M. S., Tucker G. T., Woods H. F. Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies. Br J Clin Pharmacol. 1985 Dec;20(6):555–566. doi: 10.1111/j.1365-2125.1985.tb05112.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Murray M. In vitro effects of quinoline derivatives on cytochrome P-450 and aminopyrine N-demethylase activity in rat hepatic microsomes. Biochem Pharmacol. 1984 Oct 15;33(20):3277–3281. doi: 10.1016/0006-2952(84)90090-x. [DOI] [PubMed] [Google Scholar]
  25. O'Brien J. T., Eagger S., Levy R. Effects of tetrahydroaminoacridine on liver function in patients with Alzheimer's disease. Age Ageing. 1991 Mar;20(2):129–131. doi: 10.1093/ageing/20.2.129. [DOI] [PubMed] [Google Scholar]
  26. OMURA T., SATO R. THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. J Biol Chem. 1964 Jul;239:2370–2378. [PubMed] [Google Scholar]
  27. Purba H. S., Back D. J., Orme M. L. Tolbutamide 4-hydroxylase activity of human liver microsomes: effect of inhibitors. Br J Clin Pharmacol. 1987 Aug;24(2):230–234. doi: 10.1111/j.1365-2125.1987.tb03167.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Serlin M. J., Challiner M., Park B. K., Turcan P. A., Breckenridge A. M. Cimetidine potentiates the anticoagulant effect of warfarin by inhibition of drug metabolism. Biochem Pharmacol. 1980 Jul 1;29(13):1971–1972. doi: 10.1016/0006-2952(80)90114-8. [DOI] [PubMed] [Google Scholar]
  29. Smith C. A., Gough A. C., Leigh P. N., Summers B. A., Harding A. E., Maraganore D. M., Sturman S. G., Schapira A. H., Williams A. C., Maranganore D. M. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet. 1992 Jun 6;339(8806):1375–1377. doi: 10.1016/0140-6736(92)91196-f. [DOI] [PubMed] [Google Scholar]
  30. Somogyi A., Muirhead M. Pharmacokinetic interactions of cimetidine 1987. Clin Pharmacokinet. 1987 May;12(5):321–366. doi: 10.2165/00003088-198712050-00002. [DOI] [PubMed] [Google Scholar]
  31. Stille W., Harder S., Mieke S., Beer C., Shah P. M., Frech K., Staib A. H. Decrease of caffeine elimination in man during co-administration of 4-quinolones. J Antimicrob Chemother. 1987 Nov;20(5):729–734. doi: 10.1093/jac/20.5.729. [DOI] [PubMed] [Google Scholar]
  32. Summers W. K., Majovski L. V., Marsh G. M., Tachiki K., Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med. 1986 Nov 13;315(20):1241–1245. doi: 10.1056/NEJM198611133152001. [DOI] [PubMed] [Google Scholar]
  33. Syvälahti E. K., Lindberg R., Kallio J., De Vocht M. Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br J Clin Pharmacol. 1986 Jul;22(1):89–92. [PMC free article] [PubMed] [Google Scholar]
  34. Thummel K. E., Kharasch E. D., Podoll T., Kunze K. Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1. Drug Metab Dispos. 1993 Mar-Apr;21(2):350–357. [PubMed] [Google Scholar]
  35. Tingle M. D., Coleman M. D., Park B. K. The effect of preincubation with cimetidine on the N-hydroxylation of dapsone by human liver microsomes. Br J Clin Pharmacol. 1991 Jul;32(1):120–123. doi: 10.1111/j.1365-2125.1991.tb05623.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Tingle M. D., Park B. K. Metabolism of ciamexon by human liver microsomes: an investigation into the formation of stable, chemically reactive and cytotoxic metabolites. Br J Clin Pharmacol. 1990 May;29(5):549–556. doi: 10.1111/j.1365-2125.1990.tb03678.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Wijnands W. J., Vree T. B., van Herwaarden C. L. The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol. 1986 Dec;22(6):677–683. doi: 10.1111/j.1365-2125.1986.tb02957.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Wijnands W. J., van Herwaarden C. L., Vree T. B. Enoxacin raises plasma theophylline concentrations. Lancet. 1984 Jul 14;2(8394):108–109. doi: 10.1016/s0140-6736(84)90283-6. [DOI] [PubMed] [Google Scholar]
  39. Woolf T. F., Pool W. F., Bjorge S. M., Chang T., Goel O. P., Purchase C. F., 2nd, Schroeder M. C., Kunze K. L., Trager W. F. Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species difference. Drug Metab Dispos. 1993 Sep-Oct;21(5):874–882. [PubMed] [Google Scholar]
  40. Wrighton S. A., Vandenbranden M., Stevens J. C., Shipley L. A., Ring B. J., Rettie A. E., Cashman J. R. In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab Rev. 1993;25(4):453–484. doi: 10.3109/03602539308993982. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES